MEDIGENE AG (MDG1.DE) Stock Price & Overview
FRA:MDG1 • DE000A40ESG2
Current stock price
The current stock price of MDG1.DE is 0.1335 EUR. Today MDG1.DE is down by -27.64%. In the past month the price decreased by -91.1%. In the past year, price decreased by -91.36%.
MDG1.DE Key Statistics
- Market Cap
- 1.988M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.25
- Dividend Yield
- N/A
MDG1.DE Stock Performance
MDG1.DE Stock Chart
MDG1.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MDG1.DE. When comparing the yearly performance of all stocks, MDG1.DE is a bad performer in the overall market: 99.89% of all stocks are doing better.
MDG1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MDG1.DE. MDG1.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MDG1.DE Earnings
MDG1.DE Forecast & Estimates
8 analysts have analysed MDG1.DE and the average price target is 3.88 EUR. This implies a price increase of 2803.37% is expected in the next year compared to the current price of 0.1335.
For the next year, analysts expect an EPS growth of 38.46% and a revenue growth 100% for MDG1.DE
MDG1.DE Groups
Sector & Classification
MDG1.DE Financial Highlights
Over the last trailing twelve months MDG1.DE reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -94.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.15% | ||
| ROE | -82.28% | ||
| Debt/Equity | 0.08 |
MDG1.DE Ownership
MDG1.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.55 | 37.935B | ||
| 1AE | ARGENX SE | 25.54 | 37.897B | ||
| 22UA | BIONTECH SE-ADR | N/A | 17.926B | ||
| ABVX | ABIVAX SA | N/A | 7.022B | ||
| 2X1 | ABIVAX SA | N/A | 7.014B | ||
| GXE | GALAPAGOS NV | N/A | 1.675B | ||
| GLPG | GALAPAGOS NV | N/A | 1.674B | ||
| NANO | NANOBIOTIX | N/A | 1.304B | ||
| IVA | INVENTIVA SA | N/A | 996.71M | ||
| 6IV | INVENTIVA SA | N/A | 982.175M | ||
| PHIL | PHILOGEN SPA | 18.05 | 654.976M | ||
| GNFT | GENFIT | 831.37 | 415.274M | ||
| FYB | FORMYCON AG | N/A | 318.413M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About MDG1.DE
Company Profile
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Company Info
IPO: 2000-06-30
MEDIGENE AG
Lochhamer Strasse 11
Planegg BAYERN DE
Employees: 87
Phone: 49892000330
MEDIGENE AG / MDG1.DE FAQ
What does MEDIGENE AG do?
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 86 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Can you provide the latest stock price for MEDIGENE AG?
The current stock price of MDG1.DE is 0.1335 EUR. The price decreased by -27.64% in the last trading session.
What is the dividend status of MEDIGENE AG?
MDG1.DE does not pay a dividend.
What is the ChartMill rating of MEDIGENE AG stock?
MDG1.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about MEDIGENE AG (MDG1.DE) stock?
8 analysts have analysed MDG1.DE and the average price target is 3.88 EUR. This implies a price increase of 2803.37% is expected in the next year compared to the current price of 0.1335.
What sector and industry does MEDIGENE AG belong to?
MEDIGENE AG (MDG1.DE) operates in the Health Care sector and the Biotechnology industry.